UA72433C2 - Infectious clones of rna-viruses and vaccines, and also diagnostic analyses developed on their base - Google Patents

Infectious clones of rna-viruses and vaccines, and also diagnostic analyses developed on their base Download PDF

Info

Publication number: UA72433C2
Authority: UA; Ukraine
Prior art keywords: virus; rna; nucleic acid; cells; recombinant nucleic
Prior art date: 1996-10-30

Application number

UA99052951A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-30

Filing date

1997-10-29

Publication date

2005-03-15

1997-10-29 Application filed filed Critical

2005-03-15 Publication of UA72433C2 publication Critical patent/UA72433C2/uk

Links

208000015181 infectious disease Diseases 0.000 title claims abstract description 97
230000002458 infectious effect Effects 0.000 title claims abstract description 77
229960005486 vaccine Drugs 0.000 title claims abstract description 21
238000004458 analytical method Methods 0.000 title description 4
241000700605 Viruses Species 0.000 claims abstract description 135
238000000034 method Methods 0.000 claims abstract description 31
241001493065 dsRNA viruses Species 0.000 claims abstract description 26
150000007523 nucleic acids Chemical class 0.000 claims abstract description 22
102000039446 nucleic acids Human genes 0.000 claims abstract description 17
108020004707 nucleic acids Proteins 0.000 claims abstract description 17
239000000427 antigen Substances 0.000 claims description 20
102000036639 antigens Human genes 0.000 claims description 20
108091007433 antigens Proteins 0.000 claims description 20
238000004519 manufacturing process Methods 0.000 claims description 15
108700026244 Open Reading Frames Proteins 0.000 claims description 8
108010067390 Viral Proteins Proteins 0.000 claims description 7
239000003550 marker Substances 0.000 claims description 7
108020004414 DNA Proteins 0.000 claims description 6
108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
230000000405 serological effect Effects 0.000 claims description 5
230000001018 virulence Effects 0.000 claims description 3
210000004027 cell Anatomy 0.000 description 130
239000002299 complementary DNA Substances 0.000 description 93
108091032973 (ribonucleotides)n+m Proteins 0.000 description 84
239000002773 nucleotide Substances 0.000 description 47
125000003729 nucleotide group Chemical group 0.000 description 47
239000012634 fragment Substances 0.000 description 31
230000003612 virological effect Effects 0.000 description 31
239000013612 plasmid Substances 0.000 description 27
241000282887 Suidae Species 0.000 description 21
210000001132 alveolar macrophage Anatomy 0.000 description 21
238000001890 transfection Methods 0.000 description 21
230000003834 intracellular effect Effects 0.000 description 18
108090000623 proteins and genes Proteins 0.000 description 18
210000000234 capsid Anatomy 0.000 description 15
102000004169 proteins and genes Human genes 0.000 description 15
210000002540 macrophage Anatomy 0.000 description 14
102000004190 Enzymes Human genes 0.000 description 13
108090000790 Enzymes Proteins 0.000 description 13
239000006228 supernatant Substances 0.000 description 13
108020000999 Viral RNA Proteins 0.000 description 12
239000002245 particle Substances 0.000 description 12
230000010076 replication Effects 0.000 description 12
238000013518 transcription Methods 0.000 description 12
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 11
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
244000052769 pathogen Species 0.000 description 10
230000035897 transcription Effects 0.000 description 9
101100237844 Mus musculus Mmp19 gene Proteins 0.000 description 8
230000000295 complement effect Effects 0.000 description 8
230000036039 immunity Effects 0.000 description 8
239000000047 product Substances 0.000 description 8
210000002845 virion Anatomy 0.000 description 8
102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000010367 cloning Methods 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
210000004072 lung Anatomy 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
238000012360 testing method Methods 0.000 description 7
108090001074 Nucleocapsid Proteins Proteins 0.000 description 6
108020004511 Recombinant DNA Proteins 0.000 description 6
108091027544 Subgenomic mRNA Proteins 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
238000004520 electroporation Methods 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
238000010839 reverse transcription Methods 0.000 description 6
102100034349 Integrase Human genes 0.000 description 5
101710085938 Matrix protein Proteins 0.000 description 5
101710127721 Membrane protein Proteins 0.000 description 5
101710172711 Structural protein Proteins 0.000 description 5
210000001185 bone marrow Anatomy 0.000 description 5
210000005056 cell body Anatomy 0.000 description 5
238000010276 construction Methods 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000004048 modification Effects 0.000 description 5
230000001717 pathogenic effect Effects 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
239000013598 vector Substances 0.000 description 5
241000711573 Coronaviridae Species 0.000 description 4
101710091045 Envelope protein Proteins 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
108091034117 Oligonucleotide Proteins 0.000 description 4
101710188315 Protein X Proteins 0.000 description 4
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
230000035772 mutation Effects 0.000 description 4
238000010186 staining Methods 0.000 description 4
229940126580 vector vaccine Drugs 0.000 description 4
241000282693 Cercopithecidae Species 0.000 description 3
235000010469 Glycine max Nutrition 0.000 description 3
108060003393 Granulin Proteins 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000002405 diagnostic procedure Methods 0.000 description 3
230000009977 dual effect Effects 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
238000002161 passivation Methods 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000003362 replicative effect Effects 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
241000894006 Bacteria Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
108060004795 Methyltransferase Proteins 0.000 description 2
208000035415 Reinfection Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
230000005923 long-lasting effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000013641 positive control Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000004321 preservation Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
229940023147 viral vector vaccine Drugs 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
206010000234 Abortion spontaneous Diseases 0.000 description 1
101100191372 Arabidopsis thaliana PRK5 gene Proteins 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
101100114828 Drosophila melanogaster Orai gene Proteins 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
244000089409 Erythrina poeppigiana Species 0.000 description 1
241000710831 Flavivirus Species 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
206010061192 Haemorrhagic fever Diseases 0.000 description 1
101000690503 Homo sapiens Protein argonaute-3 Proteins 0.000 description 1
102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
241000710788 Lelystad virus Species 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108091093105 Nuclear DNA Proteins 0.000 description 1
241000005308 Orsa Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
241000710778 Pestivirus Species 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
102100026791 Protein argonaute-3 Human genes 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
241000269435 Rana <genus> Species 0.000 description 1
235000009776 Rathbunia alamosensis Nutrition 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000711517 Torovirus Species 0.000 description 1
108700009124 Transcription Initiation Site Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
241000219873 Vicia Species 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
230000003321 amplification Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
208000016063 arterial thoracic outlet syndrome Diseases 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
210000003323 beak Anatomy 0.000 description 1
238000007664 blowing Methods 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
238000011109 contamination Methods 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
244000309457 enveloped RNA virus Species 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
235000010299 hexamethylene tetramine Nutrition 0.000 description 1
239000004312 hexamethylene tetramine Substances 0.000 description 1
VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
210000001865 kupffer cell Anatomy 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
208000015994 miscarriage Diseases 0.000 description 1
239000000203 mixture Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
-1 or for example Proteins 0.000 description 1
230000008520 organization Effects 0.000 description 1
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000005070 ripening Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000010415 tropism Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Virology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
Gastroenterology & Hepatology (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Analytical Chemistry (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

UA99052951A 1996-10-30 1997-10-29 Infectious clones of rna-viruses and vaccines, and also diagnostic analyses developed on their base UA72433C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP96203024A EP0839912A1 (de)	1996-10-30	1996-10-30	Ansteckende Klone von RNA-Viren und darauf basierende Impfstoffe und diagnostisches Verfahren
PCT/NL1997/000593 WO1998018933A1 (en)	1996-10-30	1997-10-29	Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof

Publications (1)

Publication Number	Publication Date
UA72433C2 true UA72433C2 (en)	2005-03-15

Family

ID=8224533

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA99052951A UA72433C2 (en)	1996-10-30	1997-10-29	Infectious clones of rna-viruses and vaccines, and also diagnostic analyses developed on their base

Country Status (23)

Country	Link
US (5)	US6268199B1 (de)
EP (2)	EP0839912A1 (de)
JP (1)	JP3921552B2 (de)
KR (1)	KR100437254B1 (de)
CN (1)	CN1138859C (de)
AT (1)	ATE366314T1 (de)
AU (1)	AU719991B2 (de)
BR (1)	BR9712592A (de)
CA (1)	CA2272046C (de)
CZ (1)	CZ294781B6 (de)
DE (1)	DE69737886T2 (de)
DK (1)	DK0935660T3 (de)
ES (1)	ES2290973T3 (de)
HU (1)	HUP9903829A3 (de)
ID (1)	ID22208A (de)
MY (1)	MY117686A (de)
PL (1)	PL191258B1 (de)
PT (1)	PT935660E (de)
SI (1)	SI0935660T1 (de)
SK (1)	SK286231B6 (de)
UA (1)	UA72433C2 (de)
WO (1)	WO1998018933A1 (de)
ZA (1)	ZA979732B (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040224327A1 (en) *	1996-10-30	2004-11-11	Meulenberg Johanna Jacoba Maria	Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0839912A1 (de) *	1996-10-30	1998-05-06	Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo)	Ansteckende Klone von RNA-Viren und darauf basierende Impfstoffe und diagnostisches Verfahren
EP0974660A1 (de) *	1998-06-19	2000-01-26	Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO)	Newcastle-Krankheitsvirus Infektiöser Klone, Impfstoffe und Diagnosetest
CA2440933A1 (en) *	1998-12-22	2000-06-22	Pfizer Products Inc.	An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
US7618797B2 (en)	1998-12-22	2009-11-17	Pfizer Inc	Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7691389B2 (en) *	1998-12-22	2010-04-06	Pfizer Inc	Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7132106B2 (en) *	1998-12-22	2006-11-07	Pfizer Inc.	Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
EP1157121B1 (de)	1999-03-08	2013-04-24	Boehringer Ingelheim Vetmedica GmbH	Prrsv replikon
ES2388909T3 (es)	1999-04-22	2012-10-19	The United States Of America, As Represented Bythe Secretary Of Agriculture	Vacuna contra el virus del síndrome respiratorio y reproductivo porcino basada en aislado JA-142 aislada
PL356274A1 (en) *	2000-01-26	2004-06-28	Boehringer Ingelheim Vetmedica Gmbh	Recombinant attenuation of prrsv
EP1156111A1 (de) *	2000-05-19	2001-11-21	Stichting Dienst Landbouwkundig Onderzoek	Chimäre Arterivirus-ähnliche Partikel
DK1857122T3 (da)	2001-06-05	2011-03-21	Curevac Gmbh	Stabiliseret mRNA med forøget G/C-indhold, kodende for et viralt antigen
DE10162480A1 (de)	2001-12-19	2003-08-07	Ingmar Hoerr	Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US6841364B2 (en)	2002-01-22	2005-01-11	Protatek International, Inc.	Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
DE10229872A1 (de) *	2002-07-03	2004-01-29	Curevac Gmbh	Immunstimulation durch chemisch modifizierte RNA
DE10347710B4 (de)	2003-10-14	2006-03-30	Johannes-Gutenberg-Universität Mainz	Rekombinante Impfstoffe und deren Verwendung
AU2005265142A1 (en)	2004-06-18	2006-01-26	Regents Of The University Of Minnesota	Identifying virally infected and vaccinated organisms
KR100872840B1 (ko)	2004-07-09	2008-12-22	(주)씨아이디	돼지생식기호흡기증후군 바이러스에 대한 전체-길이의감염성이 있는 cDNA 클론 및 이의 용도
US20060020227A1 (en) *	2004-07-20	2006-01-26	Moore Thomas E	Collection means and a method for collecting cord blood
US7632636B2 (en)	2004-09-21	2009-12-15	Boehringer Ingelheim Vetmedica, Inc.	Porcine reproductive and respiratory syndrome isolates and methods of use
CN101189027A (zh)	2005-01-13	2008-05-28	贝林格尔·英格海姆维特梅迪卡有限公司	改良的prrs疫苗
BRPI0606189A2 (pt) *	2005-02-25	2009-06-09	Pfizer Prod Inc	composição, vacina e método para proteger um animal porcino de infecção por um vìrus de prrs, célula hospedeira transfectada, método para fazer um vìrus de prrs geneticamente modificado e atenuado
MX2007015849A (es)	2005-06-24	2008-02-22	Univ Minnesota	Virus del sindrome respiratorio y reproductivo porcino, clones infecciosos, mutantes de los mismos, y metodos de uso.
CA2620667A1 (en) *	2005-08-30	2007-04-12	Board Of Regents Of The University Of Nebraska	Methods and compositions for vaccination of animals with prrsv antigens with improved immunogenicity
DE102005046490A1 (de)	2005-09-28	2007-03-29	Johannes-Gutenberg-Universität Mainz	Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP2046954A2 (de)	2006-07-31	2009-04-15	Curevac GmbH	Nukleinsäure der formel (i): gixngn, oder (ii): cixmcn, insbesondere als immunstimulierendes mittel/adjuvans
US7666585B2 (en)	2007-06-15	2010-02-23	Protatek International, Inc.	Construction of chimera PRRSV, compositions and vaccine preparations
CN101454442A (zh) *	2007-06-15	2009-06-10	普泰克国际有限公司	嵌合体prrsv的构建，组合物及疫苗的制备
JP2010531143A (ja) *	2007-06-25	2010-09-24	サウスダコタステートユニバーシティー	組換え北アメリカ１型ブタ生殖器呼吸器症候群ウイルス及び使用方法
WO2009030254A1 (en)	2007-09-04	2009-03-12	Curevac Gmbh	Complexes of rna and cationic peptides for transfection and for immunostimulation
JP5721441B2 (ja)	2008-01-31	2015-05-20	キュアバックゲーエムベーハーＣｕｒｅｖａｃＧｍｂｈ	免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体
BRPI0917887A2 (pt) *	2008-08-25	2019-09-03	Boehringer Ingelheim Vetmedica Inc	vacina contra síndrome reprodutiva e respiratória suína altamente patogênica (hp pprs)
WO2010037408A1 (en)	2008-09-30	2010-04-08	Curevac Gmbh	Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
TWI627281B (zh)	2009-09-02	2018-06-21	百靈佳殷格翰家畜藥品公司	降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
US20110053829A1 (en)	2009-09-03	2011-03-03	Curevac Gmbh	Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
ES2558106T3 (es)	2010-07-30	2016-02-02	Curevac Ag	Formación de complejos de ácidos nucleicos con componentes catiónicos disulfuro-reticulados para la transfección e inmunoestimulación
CA2807552A1 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
LT4108671T (lt)	2010-10-01	2025-01-10	Modernatx, Inc.	Modifikuoti nukleozidai, nukleotidai, nukleorūgštys bei jų panaudojimas
UA108902C2 (uk)	2010-11-10	2015-06-25		Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
EP2675475B1 (de)	2011-02-17	2015-07-01	Boehringer Ingelheim Vetmedica GmbH	Neuer europäischer prrsv-stamm
ES2553879T3 (es)	2011-02-17	2015-12-14	Boehringer Ingelheim Vetmedica Gmbh	Procedimiento para la producción a escala comercial de PRRSV
US8710200B2 (en)	2011-03-31	2014-04-29	Moderna Therapeutics, Inc.	Engineered nucleic acids encoding a modified erythropoietin and their expression
HUE046152T2 (hu)	2011-05-24	2020-02-28	Biontech Rna Pharmaceuticals Gmbh	Rák elleni egyedi vakcinák
US9187731B2 (en)	2011-07-29	2015-11-17	Boehringer Ingelheim Vetmedica Gmbh	PRRS virus inducing type I interferon in susceptible cells
EP2737059A1 (de)	2011-07-29	2014-06-04	Boehringer Ingelheim Vetmedica GmbH	Neuartiges prrs-virus zur induktion von interferon des typs i in empfindlichen zellen
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
SMT202200229T1 (it)	2011-10-03	2022-07-21	Modernatx Inc	Nucleosidi, nucleotidi e acidi nucleici modificati e loro usi
RU2649364C2 (ru)	2011-12-16	2018-04-02	Модерна Терапьютикс, Инк.	Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
WO2013113326A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013143555A1 (en)	2012-03-26	2013-10-03	Biontech Ag	Rna formulation for immunotherapy
US10501512B2 (en)	2012-04-02	2019-12-10	Modernatx, Inc.	Modified polynucleotides
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243954A1 (en)	2012-04-02	2014-10-30	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of cosmetic proteins and peptides
UA114504C2 (uk)	2012-04-04	2017-06-26	Зоетіс Сервісіз Ллс	Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk)	2012-04-04	2017-06-26	Зоетіс Сервісіз Ллс	Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en)	2012-04-04	2015-09-01	Zoetis Services Llc	Mycoplasma hyopneumoniae vaccine
CN105688201A (zh)	2012-05-17	2016-06-22	佐蒂斯有限责任公司	在断奶之前对抗猪繁殖与呼吸综合征（prrs）病毒的有效疫苗接种
HRP20220607T1 (hr)	2012-11-26	2022-06-24	Modernatx, Inc.	Terminalno modificirana rna
CA2892391C (en)	2012-11-28	2023-10-17	Biontech Rna Pharmaceuticals Gmbh	Individualized vaccines for cancer
WO2014150822A2 (en)	2013-03-15	2014-09-25	Boehringer Ingelheim Vetmedica, Inc.	Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
WO2014180490A1 (en)	2013-05-10	2014-11-13	Biontech Ag	Predicting immunogenicity of t cell epitopes
BR112016003361A2 (pt)	2013-08-21	2017-11-21	Curevac Ag	vacina do vírus sincicial respiratório (rsv)
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt)	2013-10-03	2017-09-12	Moderna Therapeutics Inc	polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
CA2925021C (en)	2013-11-01	2025-05-06	Curevac Ag	MODIFIED MESSENGER RIBONUCLE ACID (MRNA) WITH REDUCED IMMUNOSTIMULATING PROPERTIES
US10010601B2 (en)	2013-12-20	2018-07-03	Boehringer Ingelheim Vetmedica Gmbh	PRRS virus variant, European PRRS virus cDNA clone, and uses thereof
CA2936286A1 (en)	2014-04-01	2015-10-08	Curevac Ag	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
JP6398454B2 (ja) *	2014-08-13	2018-10-03	セイコーエプソン株式会社	圧電駆動装置、ロボット、及び、それらの駆動方法
WO2016045732A1 (en)	2014-09-25	2016-03-31	Biontech Rna Pharmaceuticals Gmbh	Stable formulations of lipids and liposomes
WO2016128060A1 (en)	2015-02-12	2016-08-18	Biontech Ag	Predicting t cell epitopes useful for vaccination
DK3344289T3 (da)	2015-08-31	2020-04-14	Boehringer Ingelheim Vetmedica Gmbh	Pestivirusvacciner mod medfødt tremor
WO2017059902A1 (en)	2015-10-07	2017-04-13	Biontech Rna Pharmaceuticals Gmbh	3' utr sequences for stabilization of rna
US10188725B2 (en)	2015-12-14	2019-01-29	Elanco Us Inc.	Hybrid core feline vaccines
EP3493838A1 (de)	2016-08-05	2019-06-12	Hipra Scientific, S.L.U.	Cdna-klon aus dem reproduktiven schweinevirus und einem virus für das respiratorische syndrom und verwendungen davon
KR20190085977A (ko)	2016-12-14	2019-07-19	조에티스 서비시즈 엘엘씨	젖떼기 전, 유럽의 돼지 생식기 및 호흡기 증후군 (prrs) 균주 바이러스에 대한 효과적인 백신접종
WO2018224166A1 (en)	2017-06-09	2018-12-13	Biontech Rna Pharmaceuticals Gmbh	Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
MX2020008988A (es) *	2018-02-28	2020-09-28	Regeneron Pharma	Sistemas y metodos para la identificacion de contaminantes virales.
CN116716322B (zh) *	2023-05-12	2024-05-31	中山大学	一种denv-3全长感染性克隆及其构建方法与应用

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3137631A (en) *	1959-12-01	1964-06-16	Faberge Inc	Encapsulation in natural products
US3359457A (en) *	1963-10-14	1967-12-19	Triplett Electrical Instr Co	Device for overload protection of electrical equipment
US3959457A (en) *	1970-06-05	1976-05-25	Temple University	Microparticulate material and method of making such material
US4015100A (en) *	1974-01-07	1977-03-29	Avco Everett Research Laboratory, Inc.	Surface modification
US4122167A (en) *	1977-02-09	1978-10-24	Merck & Co., Inc.	Respiratory synctial vaccine
US4205060A (en) *	1978-12-20	1980-05-27	Pennwalt Corporation	Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
US4224412A (en) *	1979-05-01	1980-09-23	Dorofeev Viktor M	Living virus culture vaccine against canine distemper and method of preparing same
DD145705A1 (de)	1979-08-31	1981-01-07	Peter Solisch	Herstellungsverfahren von organspezifischen retrovirusimmunpraeparaten fuer prophylaxe,therapie und diagnostik
US4554159A (en) *	1981-11-12	1985-11-19	Institute Merieux	Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
US4452747A (en) *	1982-03-22	1984-06-05	Klaus Gersonde	Method of and arrangement for producing lipid vesicles
US4468346A (en) *	1983-10-27	1984-08-28	The United States Of America As Represented By The Secretary Of Agriculture	Monoclonal antibodies to porcine immunoglobulins
DE3405100A1 (de) *	1984-02-14	1985-08-14	Drägerwerk AG, 2400 Lübeck	Pt-katalysator auf einem traeger als luftreinigungsmittel
US4744933A (en) *	1984-02-15	1988-05-17	Massachusetts Institute Of Technology	Process for encapsulation and encapsulated active material system
US5008050A (en) *	1984-06-20	1991-04-16	The Liposome Company, Inc.	Extrusion technique for producing unilamellar vesicles
US4921706A (en) *	1984-11-20	1990-05-01	Massachusetts Institute Of Technology	Unilamellar lipid vesicles and method for their formation
US4606940A (en) *	1984-12-21	1986-08-19	The Ohio State University Research Foundation	Small particle formation and encapsulation
US5206163A (en) *	1985-07-08	1993-04-27	Chiron Corporation	DNA encoding bovine diarrhea virus protein
US4753884A (en) *	1986-01-28	1988-06-28	Novagene, Inc.	Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
FR2602791B1 (fr)	1986-08-18	1988-11-10	Ministere Agri Direction Quali	Procede de culture du virus de la rhinotracheite infectieuse de la dinde, et vaccin prepare a partir du virus ainsi obtenu
NZ222465A (en)	1986-11-07	1992-11-25	Pasteur Institut	Nanb (non a, non b hepatitis viral) antigen
US5009956A (en) *	1987-02-24	1991-04-23	Univ Minnesota	Phospholipase A2-resistant liposomes
DE3833925A1 (de)	1988-03-11	1989-09-21	Inst Angewandte Biotechnologie	Verfahren und herstellung von virus und viralem antigen und vorrichtung hierzu
US5213759A (en) *	1988-05-05	1993-05-25	Elopak Systems A.G.	Sterilization
US4927637A (en) *	1989-01-17	1990-05-22	Liposome Technology, Inc.	Liposome extrusion method
US4944948A (en) *	1989-02-24	1990-07-31	Liposome Technology, Inc.	EGF/Liposome gel composition and method
US5132117A (en) *	1990-01-11	1992-07-21	Temple University	Aqueous core microcapsules and method for their preparation
AU7007491A (en) *	1990-02-02	1991-08-08	Schweiz. Serum- & Impfinstitut Bern	Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
CA2290906C (en) *	1991-06-06	2003-04-01	Stichting Centraal Diergeneeskundig Instituut	Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
US5846805A (en) *	1991-08-26	1998-12-08	Boehringer Ingelheim Animal Health, Inc.	Culture of swine infertility and respiratory syndrome virus in simian cells
HU217105B (hu)	1991-08-26	1999-11-29	Boehringer Ingelheim Vetmedica, Inc,	SIRS-vakcina, és eljárás a betegség diagnosztizálására
US6982160B2 (en) *	1991-08-26	2006-01-03	Boehringer Ingelheim Vetmedica, Inc.	Immunogenic compositions that include SIRS virus
MX9204885A (es)	1991-08-26	1994-05-31	Boehringer Animal Health Inc	Composicion de vacuna que comprende virus del sindrome de infertilidad y respiratorio de los cerdos.
US6042830A (en)	1992-08-05	2000-03-28	Boehringer Ingelheim Vetmedica, Inc.	Viral agent associated with mystery swine disease
US6080570A (en) *	1991-08-26	2000-06-27	Boehringer Ingelheim Vetmedica, Inc.	Method of producing a vaccine for Swine Infertility and Respiratory Syndrome
WO1993006211A1 (en)	1991-09-16	1993-04-01	Collins James E	Vaccine for mystery swine disease and method for diagnosis thereof
WO1993007898A1 (en)	1991-10-14	1993-04-29	Akzo Nobel N.V.	Porcine reproductive respiratory syndrome vaccine and diagnostic
FR2686097B1 (fr)	1992-01-14	1994-12-30	Rhone Merieux	Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) *	1992-02-27	1994-08-16	Ambico, Inc.	Thimerosal inactivated mycoplasma hyopneumoniae vaccine
TW289731B (de) *	1992-07-09	1996-11-01	Akzo Nv
US6592873B1 (en)	1992-10-30	2003-07-15	Iowa State University Research Foundation, Inc.	Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US5695766A (en) *	1992-10-30	1997-12-09	Iowa State University Research Foundation	Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US6773908B1 (en) *	1992-10-30	2004-08-10	Iowa State University Research Foundation, Inc.	Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6251397B1 (en) *	1992-10-30	2001-06-26	Iowa State University Research Foundation, Inc.	Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US6380376B1 (en) *	1992-10-30	2002-04-30	Iowa State University Research Foundation	Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US5419907A (en) *	1992-11-10	1995-05-30	Iowa State University Research Foundation, Inc.	Pathogenic porcine respiratory coronavirus
PL178609B1 (pl)	1993-02-08	2000-05-31	Bayer Ag	Izolat wirusa zespołu reprodukcyjnego i oddechowego świń zwanego PRRSV, sposób namnażania izolatu PRRSV, klon linii komórkowej, hodowla tkankowa zawierająca izolat PRRSV, szczepionka efektywna w ochronie świń przeciw PRRSV oraz sposób wytwarzania szczepionki efektywnej w ochronie świń przeciw PRRSV
ES2074950B1 (es)	1993-09-17	1996-03-16	Iberica Cyanamid	Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
EP0659885A1 (de) *	1993-12-21	1995-06-28	Akzo Nobel N.V.	Impstoffe gegen von Antikörper abhängende Vergrösserung (ADE) der Virus-Infektivität
DE4407489A1 (de) *	1994-03-07	1995-09-14	Bayer Ag	Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
ATE206455T1 (de) *	1994-04-11	2001-10-15	Akzo Nobel Nv	Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des schweins
WO1995028227A1 (en)	1994-04-15	1995-10-26	Temple University	Aqueous solvent encapsulation method, apparatus and microcapsules
DK53595A (da)	1994-05-13	1995-11-14	Iberica Cyanamid	Rekombinante PRRSV-proteiner, diagnostiske kits og vaccine indeholdende sådanne rekombinante PRRSV-proteiner
WO1996004010A1 (en)	1994-08-05	1996-02-15	Regents Of The University Of Minnesota	Vr-2332 viral nucleotide sequence and methods of use
DK0732340T3 (da) *	1995-03-14	2004-10-25	Akzo Nobel Nv	Ekspression af porcine reproduktions- og respirationssyndromviruspolypeptider i den samme celle
US5690940A (en) *	1995-06-21	1997-11-25	Regents Of The University Of Minnesota	Low pathogencity PRRS live virus vaccines and methods of preparation thereof
ES2102971B1 (es)	1996-01-25	1998-03-01	Hipra Lab Sa	Nueva cepa atenuada del virus causante del sindrome respiratorio y reproductivo porcino (prrs), las vacunas y medios de diagnostico obtenibles con la misma y los procedimientos para su obtencion.
US6015663A (en) *	1996-03-01	2000-01-18	The United States Of America As Represented By The Secretary Of Agriculture	Restriction enzyme screen for differentiating porcine reproductive and respiratory syndrome virus strains
US5866401A (en) *	1996-03-01	1999-02-02	Schering Corporation	Porcine reproductive and respiratory syndrome vaccine
SK119498A3 (en)	1996-03-01	1999-07-12	Schering Corp	Porcine reproductive and respiratory syndrome vaccine
US5976537A (en) *	1996-07-02	1999-11-02	The United States Of America As Represented By The Secretary Of Agriculture	Porcine reproductive and respiratory syndrome vaccine
PT835930E (pt) *	1996-10-09	2001-06-29	Akzo Nobel Nv	Estirpes europeias de vacina do virus do sindroma reprodutivo e respiratorio porcino (prrsv)
US20040224327A1 (en) *	1996-10-30	2004-11-11	Meulenberg Johanna Jacoba Maria	Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0839912A1 (de) *	1996-10-30	1998-05-06	Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo)	Ansteckende Klone von RNA-Viren und darauf basierende Impfstoffe und diagnostisches Verfahren
WO1998035023A1 (en)	1997-02-07	1998-08-13	Origen, Inc.	Method for growing porcine reproductive and respiratory syndrome virus for use as vaccines and diagnostic assays
HU228704B1 (en)	1997-05-06	2013-05-28	Boehringer Ingelheim Vetmed	Prrsv antigenic sites identifying peptide sequences of prrs virus for use in vaccines or diagnostic assays
IN1998CH01219A (en)	1997-06-04	2005-03-04	Calgene Llc	Production of polyunsaturated fatty acid by expression of polyketide-like synthesis genes in plants
WO1998055626A2 (en)	1997-06-05	1998-12-10	Origen, Inc.	Recombinant porcine reproductive and respiratory syndrome virus (prrsv) for use as a vaccine
US7211379B2 (en) *	1997-10-03	2007-05-01	Merial Sas	Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US6391314B1 (en) *	1997-10-03	2002-05-21	Merial	Porcine circoviruses vaccines diagnostic reagents
US7618797B2 (en) *	1998-12-22	2009-11-17	Pfizer Inc	Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7132106B2 (en) *	1998-12-22	2006-11-07	Pfizer Inc.	Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
CA2440933A1 (en)	1998-12-22	2000-06-22	Pfizer Products Inc.	An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
US7691389B2 (en) *	1998-12-22	2010-04-06	Pfizer Inc	Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
FR2789695B1 (fr) *	1999-02-11	2003-03-07	Merial Sas	Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
EP1157121B1 (de) *	1999-03-08	2013-04-24	Boehringer Ingelheim Vetmedica GmbH	Prrsv replikon
ES2388909T3 (es) *	1999-04-22	2012-10-19	The United States Of America, As Represented Bythe Secretary Of Agriculture	Vacuna contra el virus del síndrome respiratorio y reproductivo porcino basada en aislado JA-142 aislada
WO2002095040A1 (en)	2001-05-21	2002-11-28	Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V.	Delections in arterivirus replicons
US20040213805A1 (en) *	1999-10-12	2004-10-28	Verheije Monique Helene	Deletions in arterivirus replicons
US20020012670A1 (en) *	2000-01-26	2002-01-31	Knut Elbers	Recombinant attenuation of porcine reproductive and respiratory syndrome (PRRSV)
ES2267719T3 (es)	2000-02-08	2007-03-16	Regents Of The University Of Minnesota	Virus del sindrome reproductivo y respiratorio porcino y metodos de empleo.
EP1156111A1 (de)	2000-05-19	2001-11-21	Stichting Dienst Landbouwkundig Onderzoek	Chimäre Arterivirus-ähnliche Partikel
US7018638B2 (en) *	2000-12-19	2006-03-28	Wyeth	Mycoplasma hyopneumoniae bacterin vaccine
US7279166B2 (en) *	2001-12-12	2007-10-09	Virginia Tech Intellectual Properties, Inc.	Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US6841364B2 (en) *	2002-01-22	2005-01-11	Protatek International, Inc.	Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
EP1350840B1 (de) *	2002-04-05	2012-05-09	Boehringer Ingelheim Vetmedica GmbH	Sequenz Positionen zur Anpassung bei PRRSV
US7335361B2 (en) *	2003-06-09	2008-02-26	Animal Technology Institute Taiwan	Fusion antigen used as vaccine
US7722878B2 (en) *	2004-06-17	2010-05-25	Boehringer Ingelheim Vetmedica, Inc.	PRRSV subunit vaccines
AU2005265142A1 (en) *	2004-06-18	2006-01-26	Regents Of The University Of Minnesota	Identifying virally infected and vaccinated organisms
US20060063151A1 (en) *	2004-09-21	2006-03-23	Michael Roof	Porcine reproductive and respiratory syndrome isolates and methods of use
US7632636B2 (en) *	2004-09-21	2009-12-15	Boehringer Ingelheim Vetmedica, Inc.	Porcine reproductive and respiratory syndrome isolates and methods of use
CN101189027A (zh) *	2005-01-13	2008-05-28	贝林格尔·英格海姆维特梅迪卡有限公司	改良的prrs疫苗
CN106075422B (zh)	2005-11-29	2021-05-28	衣阿华州立大学研究基金公司	猪繁殖与呼吸综合征病毒(prrsv)的保护性抗原决定子的鉴定及其用途
WO2008109237A2 (en)	2007-02-13	2008-09-12	Washington State University Research Foundation	Macrophage cell-lines for propagation of porcine reproductive and respiratory syndrome virus
WO2008121958A1 (en)	2007-04-02	2008-10-09	Boehringer Ingelheim Vetmedica, Inc.	Use of prrsv vaccines to reduce pcv2 viremia
US20100003278A1 (en) *	2008-07-03	2010-01-07	Boehringer Ingelheim Vetmedica, Inc.	Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof
BRPI0917887A2 (pt)	2008-08-25	2019-09-03	Boehringer Ingelheim Vetmedica Inc	vacina contra síndrome reprodutiva e respiratória suína altamente patogênica (hp pprs)
US20100129398A1 (en) *	2008-11-26	2010-05-27	Boehringer Ingelheim Vetmedica, Inc.	Materials and Methods for Control of Porcine Reproductive and Respiratory Syndrome
DK2558118T3 (da)	2010-04-16	2019-08-26	Univ Gent	Krydsbeskyttende vaccine mod reproduktions- og respirationssyndromvirus hos svin

1996
- 1996-10-30 EP EP96203024A patent/EP0839912A1/de not_active Withdrawn
1997
- 1997-10-29 EP EP97954491A patent/EP0935660B1/de not_active Expired - Lifetime
- 1997-10-29 US US09/297,535 patent/US6268199B1/en not_active Expired - Lifetime
- 1997-10-29 PT PT97954491T patent/PT935660E/pt unknown
- 1997-10-29 AU AU58828/98A patent/AU719991B2/en not_active Expired
- 1997-10-29 ID IDW990271A patent/ID22208A/id unknown
- 1997-10-29 WO PCT/NL1997/000593 patent/WO1998018933A1/en not_active Ceased
- 1997-10-29 MY MYPI97005141A patent/MY117686A/en unknown
- 1997-10-29 UA UA99052951A patent/UA72433C2/uk unknown
- 1997-10-29 DK DK97954491T patent/DK0935660T3/da active
- 1997-10-29 ZA ZA9709732A patent/ZA979732B/xx unknown
- 1997-10-29 CN CNB97180706XA patent/CN1138859C/zh not_active Expired - Lifetime
- 1997-10-29 HU HU9903829A patent/HUP9903829A3/hu unknown
- 1997-10-29 AT AT97954491T patent/ATE366314T1/de active
- 1997-10-29 ES ES97954491T patent/ES2290973T3/es not_active Expired - Lifetime
- 1997-10-29 KR KR10-1999-7003788A patent/KR100437254B1/ko not_active Expired - Lifetime
- 1997-10-29 SI SI9730768T patent/SI0935660T1/sl unknown
- 1997-10-29 PL PL333070A patent/PL191258B1/pl not_active IP Right Cessation
- 1997-10-29 JP JP52032198A patent/JP3921552B2/ja not_active Expired - Lifetime
- 1997-10-29 CZ CZ19991564A patent/CZ294781B6/cs not_active IP Right Cessation
- 1997-10-29 DE DE69737886T patent/DE69737886T2/de not_active Expired - Lifetime
- 1997-10-29 CA CA2272046A patent/CA2272046C/en not_active Expired - Lifetime
- 1997-10-29 BR BR9712592-0A patent/BR9712592A/pt not_active Application Discontinuation
- 1997-10-29 SK SK547-99A patent/SK286231B6/sk not_active IP Right Cessation
2001
- 2001-06-05 US US09/874,626 patent/US20020098573A1/en not_active Abandoned
2003
- 2003-12-30 US US10/750,410 patent/US20040197872A1/en not_active Abandoned
2005
- 2005-09-29 US US11/239,529 patent/US8546124B2/en not_active Expired - Fee Related
2013
- 2013-09-30 US US14/041,560 patent/US20140030290A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MY117686A (en)	2004-07-31
JP2000514314A (ja)	2000-10-31
EP0935660B1 (de)	2007-07-04
PL333070A1 (en)	1999-11-08
DK0935660T3 (da)	2007-10-29
EP0839912A1 (de)	1998-05-06
JP3921552B2 (ja)	2007-05-30
CN1240481A (zh)	2000-01-05
AU5882898A (en)	1998-05-22
EP0935660A1 (de)	1999-08-18
ID22208A (id)	1999-09-16
AU719991B2 (en)	2000-05-18
HUP9903829A3 (en)	2001-06-28
CZ156499A3 (cs)	1999-09-15
US20060205033A1 (en)	2006-09-14
SK286231B6 (sk)	2008-05-06
CA2272046C (en)	2011-01-04
KR100437254B1 (ko)	2004-06-23
CZ294781B6 (cs)	2005-03-16
KR20000052920A (ko)	2000-08-25
ES2290973T3 (es)	2008-02-16
HUP9903829A1 (hu)	2000-03-28
US6268199B1 (en)	2001-07-31
US20040197872A1 (en)	2004-10-07
US20020098573A1 (en)	2002-07-25
DE69737886T2 (de)	2008-04-03
US8546124B2 (en)	2013-10-01
US20140030290A1 (en)	2014-01-30
ATE366314T1 (de)	2007-07-15
CA2272046A1 (en)	1998-05-07
BR9712592A (pt)	1999-12-21
WO1998018933A1 (en)	1998-05-07
ZA979732B (en)	1998-05-22
PL191258B1 (pl)	2006-04-28
PT935660E (pt)	2007-08-03
SI0935660T1 (sl)	2007-10-31
CN1138859C (zh)	2004-02-18
SK54799A3 (en)	2000-05-16
DE69737886D1 (de)	2007-08-16

Publication	Publication Date	Title
UA72433C2 (en)	2005-03-15	Infectious clones of rna-viruses and vaccines, and also diagnostic analyses developed on their base
JP3816126B2 (ja)	2006-08-30	組換え伝染性非セグメント化陰性鎖ｒｎａウイルス
CA2366072C (en)	2007-07-10	Prrsv vaccines
ZA200707216B (en)	2008-05-28	Replication-deficient RNA viruses as vaccines
Tang et al.	1997	Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity
KR100710519B1 (ko)	2007-04-24	일본뇌염 바이러스의 신규한 전체-길이의 게놈 ＲＮＡ 및상기 ＪＥＶ 게놈 ＲＮＡ에 대한 감염성이 있는 ＪＥＶｃＤＮＡ 및 이것의 용도
US20040224327A1 (en)	2004-11-11	Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP3865180A1 (de)	2021-08-18	Lebende rekombinante masernviren, die coronavirus-antigene exprimieren, verwendung davon zur erzeugung von immunität gegen coronaviren
US20080131459A1 (en)	2008-06-05	Full-Length Infectious Cdna Clone for Porcine Reproductive and Respiratory Syndrome Virus(Prrsv) and Uses Thereof
HK1118297B (en)	2012-08-17	Replication-deficient rna viruses as vaccines
MXPA99003967A (en)	2000-02-02	Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof